[HTML][HTML] Molecular testing in CML between old and new methods: are we at a turning point?
S Soverini, S Bernardi, S Galimberti - Journal of clinical medicine, 2020 - mdpi.com
Molecular monitoring of minimal residual disease (MRD) and BCR-ABL1 kinase domain
(KD) mutation testing have a well consolidated role in the routine management of chronic …
(KD) mutation testing have a well consolidated role in the routine management of chronic …
Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?
S Soverini, S Bernardi, S Galimberti - Journal of Clinical Medicine, 2020 - cir.nii.ac.jp
抄録< jats: p> Molecular monitoring of minimal residual disease (MRD) and BCR-ABL1
kinase domain (KD) mutation testing have a well consolidated role in the routine …
kinase domain (KD) mutation testing have a well consolidated role in the routine …
Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?
S Soverini, S Bernardi, S Galimberti - Journal of Clinical Medicine, 2020 - europepmc.org
Molecular monitoring of minimal residual disease (MRD) and BCR-ABL1 kinase domain
(KD) mutation testing have a well consolidated role in the routine management of chronic …
(KD) mutation testing have a well consolidated role in the routine management of chronic …
Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?
S Soverini, S Bernardi, S Galimberti - JOURNAL OF CLINICAL …, 2020 - iris.unibs.it
Molecular monitoring of minimal residual disease (MRD) and BCR-ABL1 kinase domain
(KD) mutation testing have a well consolidated role in the routine management of chronic …
(KD) mutation testing have a well consolidated role in the routine management of chronic …
Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?
S Soverini, S Bernardi… - Journal of clinical …, 2020 - pubmed.ncbi.nlm.nih.gov
Molecular monitoring of minimal residual disease (MRD) and BCR-ABL1 kinase domain
(KD) mutation testing have a well consolidated role in the routine management of chronic …
(KD) mutation testing have a well consolidated role in the routine management of chronic …
[PDF][PDF] Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?
S Soverini, S Bernardi, S Galimberti - J. Clin. Med, 2020 - pdfs.semanticscholar.org
Molecular monitoring of minimal residual disease (MRD) and BCR-ABL1 kinase domain
(KD) mutation testing have a well consolidated role in the routine management of chronic …
(KD) mutation testing have a well consolidated role in the routine management of chronic …
[HTML][HTML] Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?
S Soverini, S Bernardi, S Galimberti - Journal of Clinical Medicine, 2020 - ncbi.nlm.nih.gov
Molecular monitoring of minimal residual disease (MRD) and BCR-ABL1 kinase domain
(KD) mutation testing have a well consolidated role in the routine management of chronic …
(KD) mutation testing have a well consolidated role in the routine management of chronic …
Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?
S Soverini, S Bernardi… - Journal of Clinical …, 2020 - search.ebscohost.com
Molecular monitoring of minimal residual disease (MRD) and BCR-ABL1 kinase domain
(KD) mutation testing have a well consolidated role in the routine management of chronic …
(KD) mutation testing have a well consolidated role in the routine management of chronic …
Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?
S Soverini, S Bernardi, S Galimberti - JOURNAL OF CLINICAL …, 2020 - cris.unibo.it
Molecular monitoring of minimal residual disease (MRD) and BCR-ABL1 kinase domain
(KD) mutation testing have a well consolidated role in the routine management of chronic …
(KD) mutation testing have a well consolidated role in the routine management of chronic …
Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?
S Soverini, S Bernardi… - Journal of Clinical …, 2020 - search.proquest.com
Molecular monitoring of minimal residual disease (MRD) and BCR-ABL1 kinase domain
(KD) mutation testing have a well consolidated role in the routine management of chronic …
(KD) mutation testing have a well consolidated role in the routine management of chronic …